Healthcare Industry News: colorectal cancer
News Release - January 25, 2016
Exact Sciences Announces Appointment of John A. Fallon, M.D., to Company's Board of DirectorsMADISON, Wis., Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (EXAS) today announced that John A. Fallon, M.D., has joined the company's board of directors. Dr. Fallon brings more than 40 years of experience in health management, reimbursement, primary care and academic medicine to the board.
Most recently, Dr. Fallon served as chief physician executive and senior vice president of Blue Cross Blue Shield of Massachusetts, the leading health plan in that state with 3 million members. In his role at Blue Cross Blue Shield, Dr. Fallon was responsible for expanding the quality, effectiveness and efficiency of health care for its members. He oversaw the company's medical policies, evaluated healthcare technologies, acted as the liaison to the plan's providers and developed new reimbursement methods.
"Dr. Fallon's breadth of experience with health care systems, health plans and physician networks will help inform Exact Sciences' strategy and tactics across a wide range of issues, including private-payor reimbursement and physician sales," said Kevin T. Conroy, CEO and chairman of the board of Exact Sciences. "We are delighted to welcome Dr. Fallon to Exact Sciences' board of directors and look forward to his counsel, based on 40 years of experience as a health care leader."
Dr. Fallon began his career as a practicing internist. He helped to found and lead physician hospital organizations, integrated delivery systems and academic medical centers, including North Shore Medical Center, North Shore Health System, Partners Community Health Care Inc. and Partners HealthCare System. Before joining Blue Cross Blue Shield of Massachusetts, he served as chief executive officer for clinical affairs at the State University of New York Downstate Medical Center, the only academic medical center in Brooklyn. He is a fellow of the American College of Physicians and has held academic appointments since 2000.
"It's a privilege to be able to join Exact Sciences' board and engage in the company's mission of eradicating colon cancer," Dr. Fallon said. "The payor, provider and health system landscapes continue to evolve. As they do, the need for preventive tests like Cologuard only increases."
Dr. Fallon serves as a director of AMAG Pharmaceuticals Inc. and as the lead independent director at Insulet Corp. He received his bachelor's degree from the College of the Holy Cross, his medical degree from the Tufts University School of Medicine and an MBA from the University of South Florida.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is included in the U.S. Multi-Society Task Force on colorectal cancer. For more information, please follow us on Twitter @ExactSciences or find us on Facebook.
Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding potential agreements with Anthem affiliates beyond the executed agreement for California , anticipated future sales and marketing activities targeted toward Anthem members, expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products by patients and health care providers; the willingness of health insurance companies and other payors to reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and procedures; our ability to maintain regulatory approvals and comply with applicable regulations; our success establishing and maintaining collaborative and licensing arrangements; recommendations and/or guidelines issued by the U.S. Preventive Services Task Force , the American Cancer Society , or other organizations regarding cancer screening or our products and services; our ability to successfully develop new products; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Source: Exact Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.